Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 7
Opinion
Video
Case Presentation 2: Co-mutations in ESR1 and PIK3CA
Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, discuss the clinical presentation and management of a 64-year-old postmenopausal female with a history of rheumatoid arthritis who was diagnosed with stage IV, grade 3, invasive ductal carcinoma in her left breast, taking into account her comorbidities and the advanced stage of her breast cancer.
EP: 1.Prevalence and Testing Strategies for ESR1
EP: 2.Evolution of Testing Strategies for ESR1
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
EP: 6.Evolving Best Practices for ESR1 Testing
Now Viewing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
Dr. Kaklamani present Case Is: Patient with mBC, P13KCA mutation, and ESR1 mutation
Related Videos
Related Content
